We’re on a mission to fulfill the promise of genetic medicine for all patients
At Addition, we are advancing a pipeline of therapeutics to deliver functional cures for patients with severe lifelong diseases in large and rare populations.
Our CEO Ron Park, MD and CSO Francine Gregoire, PhD sat down recently with Ryan Cross, Senior Science Correspondent Endpoints News, to discuss the focused strategy driving our lead programs.
CHECK OUT RYAN’S ARTICLE HEREAbout Us
Today, the field of genetic medicine is composed of two primary modalities: RNA therapeutics and gene therapies. Both modalities have delivered important advances for patients, but each is limited to distinct applications.
At Addition, we are combining the efficacy, safety and scalability profile of RNA therapeutics with the multi-year durability of gene therapies.
Our best of both modalities approach — enabled by our PRINT technology — has the potential to further unlock the potential of genetic medicines and deliver functional cures for patients with severe lifelong diseases.
We’re focused initially on rare patient populations with severe, life-threatening unmet needs, with the goal of ultimately also addressing larger, related patient populations.
Promise
We’re committed to transformational impact for patients.
